New tool using 2D images to measure cancer risk
the ONA take:
Portuguese researchers developed a method of identifying cancer risk that uses images of a protein in a population of cells to quantify how much of the protein and where it is in the cell. The novel method was tested on cells with mutated e-cadherin, a tumor suppressor protein.
The mutation produces malfunctioning e-cadherin that causes human diffuse gastric cancer (HDGC). Gastric cancer is the fourth most common type of cancer in the world, and up to 3% of cases are HDGC. Mortality rates among patients with HDGC are high because the disease is challenging to diagnose early. E-cadherin functions as an adhesion protein that holds epithelial cells together; however, the mutated protein results in a mass of free-floating cancer cells that move and spread easily. HDGC has nonspecific symptoms, such as stomach acidity and burping, which further complicate diagnosis.
In addition, the malfunctioning e-cadherin leaves the membrane and is destroyed inside the cell. Without clear symptomatology, early diagnosis relies on searching for the lack of e-cadherin on the membrane. Test results for this effect are not reliable. The new method’s algorithm allows researchers to select more representative cells for testing.
How it works is that software designed to compute data from fluorescence images of the protein in a cell population generates a map of the protein distribution. The software then constructs 2D virtual images of a typical cell in that population, allowing researchers—and in the future clinicians—to measure the level of e-cadherin in the cell and predict the patient’s risk for HDGC.
This study focused on HDGC; however, e-cadherin mutations are known to be involved in other cancers as well, including breast, colorectal, thyroid, and ovarian cancers. The results from this study could also be applied to these cancers.
New method of identifying cancer risk that uses images of a protein in a population of cells.
Sign Up for Free e-newsletters
- Is Radioimmunotherapy a Path Forward for Melanoma?
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS
- ASCO Endorses SIO Guideline for Integrative Therapies in Breast Cancer
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Seeking Reliable Information on Herbal Products
- Disparities Remain in Prevalence of Cancer Screening Tests
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
- Combined Digital Screening Best for Detecting Breast Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|